Ziegler Capital Management, LLC Supernus Pharmaceuticals, Inc. Transaction History

Ziegler Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	BUY	$34.93 - $42.03 $7,335 - $8,826	210 Added 0.99%	21,490 $778,000
Q4 2022 Jan 24, 2023	SELL	$31.09 - $37.88 $154,268 - $187,960	-4,962 Reduced 18.91%	21,280 $0
Q3 2022 Oct 25, 2022	SELL	$28.79 - $35.41 $4,433 - $5,453	-154 Reduced 0.58%	26,242 $888,000
Q2 2022 Jul 21, 2022	BUY	$25.33 - $34.25 $18,212 - $24,625	719 Added 2.8%	26,396 $763,000
Q1 2022 May 04, 2022	SELL	$28.51 - $32.9 $59,871 - $69,090	-2,100 Reduced 7.56%	25,677 $830,000
Q4 2021 Feb 09, 2022	SELL	$26.37 - $34.22 $238,912 - $310,033	-9,060 Reduced 24.59%	27,777 $810,000
Q3 2021 Oct 27, 2021	BUY	$23.54 - $31.39 $220,381 - $293,873	9,362 Added 34.07%	36,837 $982,000
Q2 2021 Jul 21, 2021	SELL	$26.72 - $33.19 $23,540 - $29,240	-881 Reduced 3.11%	27,475 $846,000
Q1 2021 Apr 29, 2021	SELL	$24.15 - $31.45 $18,329 - $23,870	-759 Reduced 2.61%	28,356 $742,000
Q4 2020 Feb 05, 2021	BUY	$17.7 - $25.81 $103,668 - $151,169	5,857 Added 25.18%	29,115 $733,000
Q3 2020 Oct 21, 2020	BUY	$20.2 - $25.05 $469,811 - $582,612	23,258 New	23,258 $485,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Ziegler Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Ziegler Capital Management, LLC with notifications on news.